11 unchanged sentences
Purchased Under
−Removed: July 1, 2022 - July 31, 2022 893 (1)
+Added: January 1, 2023 - January 31, 2023 844 (1)
— $1,393,714,917
−Removed: August 1, 2022 - August 30, 2022 1,023 (1)
+Added: February 1, 2023 - February 28, 2023 7,306,847 (1)
7,305,832 $5,278,990,201 (2)
−Removed: September 1, 2022 - September 30, 2022 1,052 (1)
+Added: March 1, 2023 - March 31, 2023 3,035,907 (1)
3,034,981 $4,808,991,028 (2)
1 unchanged sentence
10,340,813 $4,808,991,028 (2)
−Removed: In addition to AbbVie shares repurchased on the open market under a publicly announced program, if any, these shares also included the shares purchased on the open market for the benefit of participants in the AbbVie Employee Stock Purchase Plan – 893 in July;
−Removed: 1,023 in August;
−Removed: and 1,052 in September.
+Added: In addition to AbbVie shares repurchased on the open market under a publicly announced program, if any, these shares also included the shares purchased on the open market for the benefit of participants in the AbbVie Employee Stock Purchase Plan – 844 in January;
+Added: 1,015 in February;
+Added: and 926 in March.
+Added: On February 16, 2023, AbbVie’s board of directors authorized a $5.0 billion increase to the existing stock repurchase authorization.
These shares do not include the shares surrendered to AbbVie to satisfy minimum tax withholding obligations in connection with the vesting or exercise of stock-based awards.
2 unchanged sentences
Exhibit Description
−Removed: *Form of Agreement Regarding Change in Control by and between AbbVie Inc.
−Removed: and its named executive officers (incorporated by reference to Exhibit 10.1 to the company's Current Report on Form 8-K filed on October 14, 2022).**
−Removed: AbbVie Deferred Compensation Plan Plus.**
+Added: Form of AbbVie Inc.
+Added: Performance-Vested Restricted Stock Unit Agreement*
+Added: Form of AbbVie Inc.
+Added: Performance Share Award Agreement*
+Added: Form of AbbVie Inc.
+Added: Non-Employee Director RSU Agreement (US)*
+Added: Form of AbbVie Inc.
+Added: Non-Qualified Stock Option Agreement*
+Added: Form of AbbVie Inc.
+Added: Retention RSU Agreement - Ratable Vesting*
+Added: Form of AbbVie Inc.
+Added: Non-Employee Directors’ Fee Plan, as amended and restated*
Certification of Chief Executive Officer Required by Rule 13a-14(a) (17 CFR 240.13a-14(a)).
5 unchanged sentences
101 The following financial statements and notes from the AbbVie Inc.
−Removed: Quarterly Report on Form 10-Q for the quarter ended September 30, 2022, filed on November 4, 2022, formatted in iXBRL (Inline eXtensible Business Reporting Language):
+Added: Quarterly Report on Form 10-Q for the quarter ended March 31, 2023, filed on May 5, 2023, formatted in iXBRL (Inline eXtensible Business Reporting Language):
(i) Condensed Consolidated Statements of Earnings;
7 unchanged sentences
_______________________________________________________________________________
−Removed: * Incorporated herein by reference.
−Removed: Commission file number 001-35565.
* Denotes management contract or compensatory plan or arrangement required to be filed as an exhibit hereto.
1 unchanged sentence
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
−Removed: Senior Vice President,
+Added: Executive Vice President,
Chief Financial Officer (Principal Financial Officer)
−Removed: November 4, 2022
2023 Form 10-Q |
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.